ABSTRACT: Beta genus human papillomaviruses (β-HPVs) are associated with cutaneous squamous cell 11 carcinomas (cSCCs) in a subset of immunocompromised patients. Although β-HPVs are not 12 necessary for tumor maintenance, they are hypothesized to destabilize the genome in the early 13 stages of cancer development. Supporting this idea, β-HPV's 8E6 protein attenuates p53 14 accumulation after failed cytokinesis. This paper identifies the mechanism of this abatement. We 15
show β-HPV 8E6 dysregulates the Hippo signaling pathway (HP). It increases pro-proliferative 16 gene expression, enhances TEAD activity and promotes cell growth. β-HPV 8E6 also reduces 17 LATS activation and p53-mediated apoptosis following unsuccessful division of mitotic cells. 18
These phenotypes are dependent on β-HPV 8E6 binding and destabilizing a cellular histone 19 acetyltransferase, p300. Despite circumventing apoptosis, β-HPV 8E6 caused increased 20 senescence after unsuccessful cytokinesis. We linked this lack of growth to the viral protein's 21 inability to prevent cytoplasmic sequestration of the HP transcription factor, YAP. We also show 22 that increased telomerase reverse transcriptase activity (a common alteration in cSCCs) acts 23 synergistically with β-HPV 8E6 to promote cellular proliferation after abortive cytokinesis. 24
While β-HPV 8E6 promoted aneuploidy on its own, this genome destabilization is amplified in 25 cells that do not divide after mitosis. Although our group and others have previously described 26 inhibition of DNA repair, to the best of our knowledge this marks the first time that a β-HPV 27 protein has been connected to chromosome level changes in the cellular genome. This represents 28 a substantial escalation in the known genome destabilizing properties likely to occur during a β- 29 HPV infection. 30 31 IMPORTANCE: 32 There is mounting evidence that β-HPVs contribute to cSCCs development in 33 immunocompromised populations. They may also augment UV's mutagenic potential, increasing 34 cancer risk in the general population. We demonstrate that β-HPV 8E6 dysregulates the Hippo 35 signaling pathway (HP). HP regulates cell growth and apoptosis in response to a myriad of 36 stimuli, including failed cytokinesis. β-HPV 8E6 attenuates phosphorylation of the HP kinase, 37 LATS, decreasing some but not all downstream signaling events. This allows binucleated cells to 38 avoid apoptosis, however they succumb to senescence. We show that β-HPV 8E6 synergizes 39 with a common cSCC mutation (telomerase activation) to avoid both apoptosis and senescence. 40 We did not find any telomerase immortalized β-HPV 8E6 expressing cells that were not 41 aneuploid after aberrant cytokinesis. This represents a substantial escalation in β-HPV E6's 42 known mutagenic potential. 43 44 45 INTRODUCTION: 46 The human papillomavirus (HPV) family includes over 200 double-stranded DNA viruses that 47 are divided into five genera, all of which infect human epithelia (1) . Upon infecting mucosal or 48 cutaneous tissue, members of each genera can cause a broad array of pathologies. Of these, the 49 most prominent diseases are the anogenital and oropharyngeal carcinomas caused by alpha genus 50
HPVs (2, 3). Cutaneous beta genus HPVs (β-HPVs) have also been linked to tumorigenesis via 51 high viral DNA loads in cutaneous squamous cell carcinomas (cSCCs) of immunocompromised 52 patients, primarily in areas of the skin exposed to the sun (4-6). 53 54 β-HPV infections are common in the general population, but their contribution to cSCCs is less 55 clear in immune competent individuals. The main aetiological factor in skin cancer pathogenesis 56 is UV. Further, characterizations of cSCCs in the general population do not find continued β-57
HPV expression (7-9). Viral loads decrease as lesions progress from precancerous actinic 58 keratosis (AK) lesions to cSCCs (10-12). These data have led to the hypothesized "hit and run" 59 mechanism of oncogenesis, where β-HPVs cooperate with UV to enhance genomic instability in 60 the early stages of carcinogenesis (10, 13, 14). The elevated mutational load then increases the 61 chances of tumor progression independent of continued viral gene expression. 62 63
While it is hard to prove the role of a transient viral infection in a persistent cancer, β-HPVs are 64 also a common resident of our skin and frequently found in AKs. β-HPV 8E6 increases TEAD responsive genes in a p300-dependent manner. 292 Animal models show that certain β-HPV E6 genes can contribute to UV's carcinogenesis (18, 293 19, 23). In vitro studies from our group and others have added molecular details by describing β-294 HPV E6's ability to impair the DDR by destabilizing p300 (18, 22, 27, 28, 46). However, β-HPV 295 E6's oncogenic potential probably extends beyond DDR inhibition, as it can induce skin tumors 296 in mice without UV exposure (18). Further, p300 is a master transcriptional regulator, meaning 297 the impact of its destabilization is unlikely to be confined to DDR pathways (29, 30) . There are 298 DDR-independent pathways that protect genome fidelity, whose inhibition would be consistent 299 with the "hit and run" model by which β-HPV infections are believed to contribute to cSCCs 300 (47-49). To identify p300-regulated pathways that could contribute to β-HPV E6-associated 301 genome destabilization, we performed an in silico screen by comparing RNAseq data among 302 1020 cancer cell lines grouped by their relative p300 expression levels, mimicking β-HPV 8E6 303 expression (Supplementary Data 1) (35, 50, 51). We identified genes that were upregulated (p-304 value<0.05) when p300 was decreased (z-score<-1.64). Next, gene ontology (GO) analysis was 305 performed using GOrilla to identify pathways that were significantly altered when p300 306 expression was reduced (52, 53). This revealed significant up-regulation of genes involved in the 307 HP ( Fig. 1A) , specifically TEAD1/4 which are transcriptional activators that promotes cell 308 proliferation and restrict apoptosis (54, 55). We then performed a more detailed analysis of the 309 154 HP genes using KEGG to define the pathway. When p300 expression was reduced, many 310 canonical HP genes were up-regulated. However, the most striking changes occurred in pro-311 proliferative TEAD-responsive genes (CYR61, CTGF, AXL, SERPINE1) ( Fig. 1B) . 312 313
Because β-HPV infect the cutaneous epithelia, we chose HFKs as a relevant in vitro model for 314
validating our computational data. Vector control (LXSN), β-HPV 8E6 expressing HFKs were 315 generated. To confirm p300 dependence, HFKs expressing β-HPV Δ8 E6 (residues 132-136 316
were deleted) were also generated. This mutant can no longer bind or destabilize p300 (56). RT-317
qPCR indicated that β-HPV 8E6 did not significantly change the expression of HP genes (Fig.  318  1C) . However, two pro-proliferative TEAD-responsive genes were upregulated, CTGF and 319 CYR61 (Fig. 1C) . Although, only CTGF's increase was statistically significant these results 320 parallel our in silico analysis (Fig. 1C) . To test whether this change in transcription would 321 manifest at the protein level, we observed HP protein abundance by immunoblot. β-HPV 8E6 322 increased LATS and CTGF protein levels (Fig. 1D ). Confirming HPV E6 expression, p300 was 323 significantly decreased (Fig. 1D) . These data suggested that β-HPV E6 increases TEAD activity, 324 so we used a TEAD-responsive luciferase promoter (57). β-HPV 8E6 caused a slight, but 325 significant increase in luciferase, consistent with an ability to elevate TEAD promoter activity 326 (Fig. 1E) . As a functional readout of HP activation, we defined cell proliferation rates. Compared 327 to vector control HFKs, β-HPV 8E6 increased growth in a p300-dependent manner, over a 5-day 328 period (Fig. 1F) . 329 330 β-HPV 8E6 increases the tolerance of failed cytokinesis in a p300-dependent manner.
331
H2CB blocks cytokinesis via inhibiting actin polymerization, inducing tetraploidy. This activates 332 the HP through LATS phosphorylation (32). Since we found decreased p300 expression 333 correlated with enhanced TEAD activity, we hypothesized that β-HPV 8E6 hindered the HP's 334 upstream protein's response to unsuccessful division after mitosis by binding and destabilizing 335 p300 ( Fig. 1 ). Our first step towards testing this hypothesis was to characterize H2CB activity in 336 human osteosarcoma-derived U2OS and HFK cells expressing vector control, β-HPV 8E6, or β-337 HPV Δ8 E6. Binucleation was visualized by brightfield microscopy ( Fig. 2A and 2B ). H2CB 338 universally increased the frequency of cells with more than one nucleus. Overall, there was an 339 8.5-fold increase in U2OS cells (8.6% ± 6.7% versus 72.7% ± 11.7%, n=3, P < 0.05) and a 7.45-340
fold increase in HFK cell lines (7.4% ± 1.4% versus 55.3% ± 5.0%, n=3, P < 0.05) ( Fig. 2C and  341  2D ). There was no statistical difference in H2CB-induced failed cytokinesis among the cell lines. 342
Next, we began defining the cellular response to endoreplication without proper separation. 343 U2OS cells were seeded at equal density and tracked for five days after H2CB treatment. As 344 expected, inhibiting cell division was toxic with only fractions of the starting population of 345 vector control cells remaining at the end of our time course (46.1% ± 5.6% of the cells initially 346 seeded). β-HPV 8E6 significantly reduced H2CB's deleterious effects (79.7% ± 12.8% of the 347 original population) ( Fig. 2E ). β-HPV Δ8E6 behaved indistinguishably from wildtype cells 348 consistent with a p300-dependent mechanism of action (56.9% ± 7.6% of the starting population) 349 ( Fig. 2E) . A similar trend was seen in HFKs expressing vector control, β-HPV 8, or -Δ8E6, 350
where β-HPV 8E6 expressing cells had reduced cell death when treated with H2CB over the 351 course of 5 days (Fig. 2F) . Using Ki-67 as a proliferation marker (58), we found that despite 352 allowing more cells to survive H2CB, β-HPV 8E6 did not promote growth (Fig. 2G ). 353 354 β-HPV 8E6 attenuates p53 accumulation induced by failed cytokinesis by inhibiting 355 pLATS activation. 356 We previously reported that β-HPV 8E6 attenuated p53 stabilization after spontaneous 357 binucleation (25). We used immunofluorescence microscopy and immunoblotting to confirm that 358 this phenotype was maintained in cells exposed to H2CB. β-HPV 8E6 prevented the increase in 359
p53-staining seen in vector control cells grown with H2CB ( Fig. 3A and 3B ). Consistent with 360 past observations, the frequency of p53 staining and binucleation were equivalent in vector 361 control (59.5% ± 4.3% vs. 51.35% ± 1.4) ( Fig. 2C and 3B ). Validating the immunofluorescence 362
data, immunoblot analysis confirmed that β-HPV 8E6 expressing cells limited p53 accrual when 363 binucleated (Fig. 3C) . Supporting a p300-dependent mechanism, β-HPV Δ8E6 did not suppress 364 p53 induction (Fig. 3A-D) . Interestingly, we did not see the increase in PI-positive cells after 365 H2CB treatment that we had anticipated (Fig. 3E ). 366 367 LATS activation is necessary for p53 to accumulate in tetraploid cells (32). To determine if β-368 HPV 8E6 reduced p53 accumulation by attenuating LATS phosphorylation, we induced failed 369 cytokinesis and detected pLATS. Vector control cells showed a sharp increase in phosphorylated 370 LATS (pLATS) relative to total LATS (Fig. 3F ). Only total LATS levels increased when β-HPV 371 8E6 was expressed (Fig. 3D ). The induction of LATS phosphorylation in β-HPV Δ8E6 HFKs 372 resembled the response in control cells, consistent with a p300-dependent mechanism (Fig. 3F ). 373 374
A branch point in the HP occurs with LATS activation, which stabilizes p53 and phosphorylates 375
YAP. This sequesters YAP in the cytoplasm preventing it from promoting transcription of pro-376 proliferative TEAD-responsive genes (57, 59, 60). To understand the breadth of β-HPV 8E6's 377 HP dysregulation, we examined YAP sequestration by immunofluorescence microscopy. YAP 378 translocated from the nucleus to cytoplasm in binucleated vector control HFKs (Fig. 3G-H) . 379
Neither β-HPV 8E6 nor β-HPV Δ8E6 changed this. Since YAP is a TEAD co-transcriptional 380 activator, an increase in cytoplasmic YAP should result in a drop in TEAD activity (61). 381
Utilizing the TEAD-reporter assay from Fig. 1E , we found that TEAD-driven transcription was 382 reduced by H2CB-induced binucleation equally among the cell lines (Fig. 3I ). While H2CB 383 treatment significantly increased expression of STK4/MST1 and YAP in vector control HFKs, 384
LATS expression remained constant. β-HPV 8E6 did not alter these changes (Fig. 3J ). 385
Consistent with specific inhibition of LATS activation, β-HPV 8E6 did not change the 386 abundance of the other HP proteins (Supplemental Fig. 1A) . 387 388 β-HPV 8E6 limits apoptosis in cells recovering from failed cytokinesis. 389 Elevated p53 levels induce apoptosis in cells that do not divide after mitosis (32, 62). β-HPV 390 8E6's ability to reduce H2CB toxicity and diminish p53 accumulation, suggests that it limits 391 apoptosis ( Fig. 2E-F and 3A-D) . However, we did not see increased apoptosis in any of the cells 392 grown in H2CB for 24 hours (Fig. 3D ). We hypothesized that apoptosis plays a larger role in 393 rebounding from aberrant cytokinesis. To test this, we observed cells after H2CB was removed. 394
There were no significant changes in binucleation frequency in vector control HFKs. However, 395 β-HPV 8E6 caused a significant decrease in supernumerary nuclei frequency (59.5% ± 1.0% vs 396
36.3% ± 1.3%) (Fig. 4A ). β-HPV Δ8E6 HFKs remain binucleated like vector control cells. (Fig.  397 4A). Qualitative observations indicated that LXSN HFKs were dying and or becoming 398 senescent. In contrast, β-HPV 8E6 expression allowed cells to undergo another round of 399 replication, after which they frequently became mononucleated and heavily vacuolated 400
( Supplementary Fig. 1B) . 401 402
To determine if β-HPV 8E6 retained its ability to suppress LATS, we observed cells when H2CB 403 was removed. Immunoblots demonstrated that β-HPV 8E6 continued to attenuate the normal 404 LATS phosphorylation (Fig. 4B) . Similarly, immunofluorescence microscopy found β-HPV 8E6 405 decreased both the frequency and intensity of p53 staining ( Fig. 4C-E ). There was a notable 406 similarity between the frequency of p53 staining and binucleation as cells recovered (Fig. 4A , D-407 E). As we predicted, apoptosis was a typical response to H2CB removal that paralleled both p53 408 induction and binucleation ( Fig. 4A and E-F). β-HPV 8E6, but not β-HPV Δ8E6, decreased 409 apoptosis after H2CB (Fig. 4F) . Thus, β-HPV 8E6's attenuation of p53 accumulation minimized 410 cell death in response to abortive cytokinesis. 411 412 β-HPV 8E6 increases senescence during resolution of failed cytokinesis. Despite avoiding 413 apoptosis, β-HPV 8E6 did not completely absolve cells from the consequence of failed 414 cytokinesis. Cell morphology, stifled proliferation, and reduced apoptosis led us to suspect that 415 β-HPV 8E6 increased senescence (63, 64). We used Ki67 staining to define proliferation. β-HPV 416 8E6 had markedly lower Ki67 intensity during and after H2CB treatment ( Fig. 5A and 5B 572.0 417 ± 183.6 and 699.1 ± 278.6 respectively). We used senescence-associated β-Galactosidase (SA β-418
Gal) activity as a marker of senescent cells (65). β-HPV 8E6 significantly increased the 419 frequency of SA β-Gal staining after H2CB was removed (52.0% ± 7.0% vs 78.5% ± 6.8%) 420
( Fig. 5C-D) . Immunofluorescence microscopy and subcellular fractionation show that post-421 H2CB, cytoplasmic YAP sequestration was analogous among our cell lines, meaning this branch 422 of the HP remained in tacked, despite muted the LATS phosphorylation caused by β-HPV 8E6 423 ( Fig. 5E-5G ). These data are consistent with β-HPV 8E6 allowing cells to escape apoptosis only 424
to "get caught" by senescence. 425 426
TERT allows cells to bypass senescence and recover after H2CB-induced failed cytokinesis. 427
Curious as to whether mutations common in cSCC were associated with bypassing senescence, 428
we queried sequencing data from 68 cutaneous cSCC samples (38, 39) . First, we identified 429 mutated genes in cSCCs and ranked them by their frequency. The top 10% of these genes were 430
analyzed using the web-based gene ontology software, PANTHER (Supplementary Data 2) (42, 431 43, 66) Proliferation and senescence were identified as biological processes commonly altered in 432 cSCCs and expected to limit senescence. Of the relevant genetic changes, TERT activation was 433 selected because it was independently verified to be common in cSCCs (67-70). We used 434 previously characterized keratinocytes immortalized by telomerase activation and transduced 435 with HA-tagged β-HPV 8 E6 or vector control (TERT-HFK LXSN and TERT-HFK β-HPV 8E6) 436
(71, 72). 437 438
To determine if β-HPV 8E6 and TERT activation synergize, we exposed cells to H2CB for 3 439 days and monitored their recovery over time after the drug was removed. Although β-HPV 8E6 440 could mitigate some of H2CB's short term toxicity, we were never able to get HFKs to grow for 441 more than a few passages after H2CB. In contrast, TERT activation alone and in combination 442 with β-HPV 8E6 allowed them to sustain growth after 3-days of H2CB treatment (Fig. 6B ).
443
Binucleation was increased by TERT activation with and without β-HPV E6 (51.4% ± 3.5% vs 444 87.9% ± 2.9%), (Fig. 6C) . SA β-Gal staining was increased in all TERT-HFKs exposed to H2CB 445 (19.6% ± 3.6% vs 63.4% ± 3.8%), (Fig. 6D ). Of the senescent cells, the fraction that had ≥2 446 nuclei increased in TERT-HFKs (19.2% ± 0.9% vs 88.8% ± 3.7%), (Fig. 6E ). 447 448 β-HPV 8E6 and TERT activation synergize, allowing genetically unstable cells to 449 proliferate. 450
Although telomerase activation alone allowed cells to recover from failed cytokinesis, we 451
wanted to determine if this ability could be augmented by β-HPV 8E6 after extended H2CB 452 treatment. To this end, we grew cells in H2CB for an additional 3 days. The longer exposure 453 resulted in a notably lower TERT-HFK LXSN cell survival (Fig. 7A) . In contrast, TERT-HFK β-454 HPV 8E6 cells rebounded every time (Fig. 7A ). When both cell lines lived, β-HPV 8E6 455 expression made them resume normal growth rates sooner (Fig. 7B ). We hypothesized that 456 surviving had high costs regarding genome stability and tested this idea by examining changes in 457 ploidy (Fig. 7C ). After H2CB exposure, polyploidy and aneuploidy dominated, with most cells 458 having ~96 chromosomes ( Fig. 7D-E) . Chromosome abnormalities were further exacerbated by 459 β-HPV 8E6 with and without H2CB ( Fig. 7D-E differentiation. Much of its ability to disrupt DNA repair has been linked to its destabilization of 467 p300. We show that the reduction of p300 also hinders the HP's activation. Adding to the 468 mechanisms known to promote cell growth, reduced HP activity is accompanied by slightly 469 increased proliferation and elevated pro-proliferative TEAD activity. However, β-HPV 8E6 also 470 allows binucleated cells to avoid apoptosis. More specifically, β-HPV E6 attenuates LATS 471 phosphorylation leading to a blunted p53 response. While this temporarily promotes 472 proliferation, senescence acts as a failsafe mechanism preventing extensive growth of these 473 damaged cells. This checkpoint can be bypassed if β-HPV 8E6 is expressed in cells immortalized 474 by telomerase activation. Consistent with dysregulation of the cell's response to failed 475 cytokinesis, β-HPV 8E6 increased chromosomal instability (i.e., aneuploidy). 476 477
The strongest criticism of the idea that β-HPV infections contribute to cancer, is the fact that 478 most people get infected but significantly fewer people get cSCCs. We show that β-HPV 8E6's 479 ability to cause genome instability is enhanced by telomerase activation, suggesting that β-HPV 480
infections may be more tumorigenic in certain groups of people. The same principle would apply 481 within an individual as well. If such an "at risk" group(s) exists, mutations in the host cell's 482 genome at the time of infection would matter as much as whether a viral infection occurred. This 483 could explain the current struggles of epidemiologists to link β-HPVs to skin cancers, as existing 484
observations have largely focused on the presence/absence of β-HPV. Relevant to the work 485 presented here, telomerase activating mutations are common during cSCC development (68, 69). 486 487
We also extend the long history of using viral oncogenes to learn about cell biology. Our data 488 links p300 to the HP and TEAD responsive gene expression. We also confirm that LATS is 489 activated in binucleated cells. Moreover, we show that senescence is triggered in binucleated 490 cells that bypass apoptosis and that telomerase activity is a limiting factor in the propagation of 491 binucleated cells. Our observation that cells sense and respond to the disruption of actin 492 polymerization before it culminates in a binucleated cell is novel. Finally, we show that the 493 deleterious effects of failed cytokinesis increase when resolution of the ensuing polyploidy is 494 delayed. 495 496
Others have suggested that β-HPV influences the HP, most notably by binding PTPN14 (75). 497
Genus α HPV oncogenes also dysregulate the pathway (76, 77). Our data adds another link 498
between HPVs and the HP. The shared manipulation of the HP suggests HPVs gain an 499 evolutionary advantage by abrogating the signaling cascade. The "motivation" could stem from 500 the modest growth advantage that we report; however, this weak phenotype seems unlikely to 501 drive convergent evolution toward HP dysregulation. Given the HP's role in immunity, it is more 502 enticing to speculate that targeting the HP helps HPVs avoid an immune response (78, 79). 503
Indeed, an MST1 deficiency leads to more prevalent β-HPV infections (80). Since the HP was 504 only discovered 14 years ago (81), there could be other currently unknown advantageous to be 505 gained by disrupting the pathway. 506 Acknowledgements: 507 508
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